EcoDrugPlus

Free Fatty Acid Receptor 1

Ensembl ID : ENSCPOG00000037551
Gene Symbol: FFAR1
3 Cross references
75 Possible Orthologues:

Free Fatty Acid Receptor 1-Like

Ensembl ID : ENSCPOG00000036207
Gene Symbol: LOC100721783
3 Cross references
75 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSCPOG00000033507
Gene Symbol: FFAR2
4 Cross references
339 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSCPOG00000006954
Gene Symbol: FRK
2 Cross references
217 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSCPOG00000000553
Gene Symbol: GLA
2 Cross references
197 Possible Orthologues:

Galectin 1

Ensembl ID : ENSCPOG00000031838
Gene Symbol: LGALS1
2 Cross references
331 Possible Orthologues:

Galectin 3

Ensembl ID : ENSCPOG00000038163
Gene Symbol: LGALS3
2 Cross references
219 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSCPOG00000006871
Gene Symbol: GABRA1
4 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSCPOG00000023215
Gene Symbol: GABRA2
4 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSCPOG00000001196
Gene Symbol: GABRA3
4 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSCPOG00000009388
Gene Symbol: GABRA4
2 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSCPOG00000004165
Gene Symbol: GABRA5
4 Cross references
265 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).